Ann: MDR September 2017 Quarterly Report & Appendix 4C, page-2

September 2017 Quarterly Report & 4C

Highlights

• Record revenue for Q1 of $1.6 million, representing an increase of 12% on the June 2017 quarter ($1.4m) and 218% ahead of the September 2016 quarter.

• Cash receipts totalled $1.36m vs $1.4m the June 2017 quarter.

• Positive operational performance and growth across key metrics: o 925,000+ patients now using the MedAdvisor platform, an increase of 11% on the June 2017 quarter o Pharmacy subscribers now total 2,670+, representing nearly ~50% of Australian pharmacies and highlighting the value being realised throughout the industry.

• PlusOne platform roll out is progressing well with early benefits being realised and professional services revenues increasing.

• Overseas advisors appointed to assist the company to accelerate its international expansion strategy.

• Following the achievement of the performance milestones all 195M A Class Performance Shares have been converted to Ordinary Shares, with founders and management opting to voluntarily escrow their vested Performance Shares and the majority of existing Ordinary Shares for an additional period.




http://www.aspecthuntley.com.au/doc...lc2lnbmFsL2Vycm9ycGFnZXMvcGRmZGVsYXllZC5qc3A=